Unlike other β-lactamases, AmpC β-lactamases (AmpCs) are not inhibited by β-lactamase inhibitors and cephamycins. AmpC-producing organisms are generally resistant to broad-spectrum penicillins, oxyimino- and 7-α-methoxy-cephalosporins, and aztreonam, but are susceptible to cefepime, cefpirome, and carbapenems \[[@B1]\]. Although AmpC acquisition was first detected in Korea in 1988 \[[@B2]\], there remains a lack of awareness about its importance. One reason for this is that most clinical laboratories do not attempt to detect and report this resistance mechanism. Previously, we reported an increased trend in the acquisition of AmpC-mediated resistance in *K. pneumoniae* isolates in a hospital in Korea, from 2002 to 2004 \[[@B3]\]. In this study, we investigated the occurrence and genetic basis of AmpC-mediated antibiotic resistance by examining *Escherichia coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis* isolates at the same hospital, from 2007 to 2010.

Between 2007 and 2010, we collected a total of 6,932 consecutive, non-duplicate *E. coli* (n=5,152), *K. pneumoniae* (n=1,438), and *P. mirabilis* (n=367) isolates. Microbial identification was carried out using the Vitek 2 system (bioMerieux Vitek, Hazelwood, MO, USA). Cefoxitin nonsusceptibility (minimum inhibitory concentration \[MIC\] ≥16 µg/mL) was used as an indicator for AmpC acquisition. The cefoxitin-nonsusceptible isolates were tested by multiplex AmpC PCR \[[@B4]\]. AmpC detection by PCR was further confirmed by *amp*C gene sequencing. Sequence alignment and analysis was performed on-line using the National Center for Biotechnology Information BLAST algorithm. AmpC PCR-positive isolates were further investigated for β-lactamase production, as well as susceptibility to various antimicrobial agents. Susceptibility was determined by the broth microdilution test, according to the guidelines prescribed by CLSI \[[@B5]\]. The antimicrobial agents used were cefoxitin (Sigma-Aldrich Co., Steinheim, Germany), cefotaxime (Sigma-Aldrich Co.), cefepime (Boryung Co., Ltd., Seoul, Korea), imipenem (Merck & Co., West Point, PA, USA), and meropenem (Yuhan Co., Ltd., Seoul, Korea). AmpC PCR-positive isolates were also analyzed by the boronic acid (BA) disk test \[[@B6]\]. Following the combination disk method (CLSI) extended-spectrum β-lactamase (ESBL) confirmatory methodology, an increase in zone diameter by≥5 mm of CAZ-CA and/or CTX-CA in combination with BA (CAZ-CA-BA and/or CTX-CA-BA) over that of CAZ and/or CTX-containing BA (CAZ-BA and/or CTX-BA) was considered a positive test result for ESBL. Carbapenem-nonsusceptible isolates were further investigated by the modified Hodge test \[[@B7]\] and the carbapenemase inhibition test \[[@B8]\] for carbapenemase production, and were additionally investigated by SDS-PAGE for alterations in outer membrane protein expression \[[@B9]\].

AmpCs (DHA-1, CMY-2, and CMY-1) were detected in 1.6% (85/5,152; 39 DHA-1, 45 CMY-2, and 1 CMY-1) of *E. coli* isolates, 7.2% (93/1,438; 93 DHA-1, 10 CMY-2, and 1 CMY-1) of *K. pneumoniae* isolates, and 2.5% (9/367; 8 CMY-2 and 1 CMY-1) of *P. mirabilis* isolates ([Table 1](#T1){ref-type="table"}). In Korea, the isolation rate of AmpC-producing *E. coli* was 1.5% in 2002 \[[@B10]\]. Our previous study revealed that the isolation rate of AmpC-producing *K. pneumoniae* from 2002 to 2004 was 2.9%, and no AmpC-producing *P. mirabilis* strains were isolated during that period \[[@B3]\]. While the distribution of AmpC genotypes is similar to that obtained in the previous study \[[@B3]\], of the 198 acquired AmpC producers, 58 isolates (29.3%) also produced an ESBL (data not shown). This rate is much higher than that (8.7%) observed in our previous study \[[@B3]\]. In the case of the acquired AmpC-producing *K. pneumoniae* isolates, ~50~/MIC~90~ values for cefoxitin, cefotaxime, cefepime, imipenem, and meropenem were \>32/\>32, 16/\>32, 1/16, 0.25/0.5, and \<0.125/0.125 µg/mL, respectively ([Table 2](#T2){ref-type="table"}). MIC values for carbapenem were≥2 µg/mL, for only 2 of the *K. pneumoniae* isolates. Both isolates carried the *bla*~DHA-1~ gene with a loss of OmpK36 expression, but were negative for carbapenemase production (data not shown). In Korea, AmpC (DHA-1) expression, in combination with a loss in OmpK35/36 expression contributes to the carbapenem resistance observed in *Enterobacteriaceae*, and this phenotype is associated with a poor clinical outcome \[[@B11], [@B12]\].

In summary, there has been an increase in the clinical isolation of acquired AmpC-producing *K. pneumoniae*, as well as an increase in the isolation of AmpC and ESBL co-producers in recent years in Korea. DHA-1 was the predominant AmpC enzyme in the *K. pneumoniae* isolates, while CMY-2 was predominantly found in *E. coli* and *P. mirabilis* isolates. The accurate identification of isolates producing AmpCs and ESBLs may aid in infection control, and will provide valuable guidance while selecting an appropriate antibiotic regimen.
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^\*^The MICs of 2 carbapenem-nonsusceptible *K. pneumoniae* isolates for imipenem and meropenem show \>32 and 8 µg/mL and 16 and 4 µg/mL, respectively.

Abbreviation: MIC, minimum inhibitory concentration.
